Roche’s test of novel gut target nears
Pivotal ulcerative colitis data on etrolizumab, a dual-action anti-integrin antibody, are due soon, and Roche has Takeda’s Entyvio in its sights.
Upcoming events – Filgotinib's ulcerative colitis data and serlopitant takes on pruritus
Gilead and Galapagos's filgotinib might not be a match for Rinvoq in ulcerative colitis, while Menlo needs to prove serlopitant works after previous setbacks.
Index heads for another dubious pivotal trial
Six years after failing phase III cobitolimod underwhelms in phase II, but Index ploughs on into a fresh pivotal study.
Olympus banks on acquisitions to sustain its high
A strategic change towards Olympus's medical business, and particularly therapeutic procedures, has reignited growth. Next up: acquisitions.
Upcoming events – Gilead’s Nash refocus and an early chance for Ionis and Roche
Data from Gilead's Atlas combination trial in Nash could point to a way forward, while Roche and Ionis are hoping to confirm earlier signals seen with a…
Speedy nod sets Alnylam up for its second launch
Alnylam unveils a novel pricing strategy for its second RNAi launch, which was greenlit by the US regulator with notable speed.
9 Meters must go a lot further than that
Innovate combines with RDD, but the success of the takeover relies in large part on a project for coeliac disease.
Genfit’s liver disease Hail Mary approaches
Genfit's quiet delay means it will be five years since a Nash failure before investors find out whether pressing on into phase III was worth it.
Upcoming events – Reneuron’s conference data and Provention takes on Crohn’s
Reneuron is set to release further data with its hRPC stem cell therapy in retinitis pigmentosa, while Provention Bio aims to target Crohn’s early with PRV-6527.
